<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146289</url>
  </required_header>
  <id_info>
    <org_study_id>502.469</org_study_id>
    <nct_id>NCT00146289</nct_id>
  </id_info>
  <brief_title>The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects</brief_title>
  <official_title>A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether MICARDIS® improves insulin
      sensitivity in overweight or obese, non-diabetic, normotensive subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the change from baseline to the end of study (16 weeks) in the insulin sensitivity index as estimated by the composite index (R04-1184) calculated from a 3-hour oral glucose tolerance test (OGTT).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>From baseline: Glucose disposal rates; Insulin sensitivity (IS) index as Rd/I (clamp); IS index (OGTT- min model); Insulin secretion capacity; fasting insulin &amp; gluc.; AUC gluc &amp; insulin; ratio of AUC glucose ÷ by AUC insulin; lipids &amp; inflam. markers.</measure>
  </secondary_outcome>
  <enrollment>138</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MICARDIS® (telmisartan)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation.

          2. Subjects 18-65 years old.

          3. Body Mass Index (BMI) &gt;= 28.

          4. Sedentary life style defined as: Does not engage in vigorous activity for more than 30
             minutes per day, more than two times per week.

          5. Waist circumference &gt;= 40 inches (102 cm) in men and &gt;= 35 inches (89 cm) women.

          6. HbA1C assessed &lt;= 6.5%.

          7. Triglycerides &gt;= 150, and &lt;= 500 mg/dL.

          8. Fasting Glucose &lt;= 126 mg/dL.

          9. Blood pressure &gt;= 110/64 and &lt;= 140/90 mmHg.

        Exclusion Criteria:

          1. Currently taking any antihypertensive medications (e.g., thiazide or loop diuretics),
             diabetic medications, medications known to alter insulin sensitivity (e.g., statins),
             steroids, glucocorticoids, niacin, nicotinic acid, and anti-psychotic/depressant drugs
             (e.g., prozocin). Including over the counter (OTC) and herbal products, which are
             known to affect metabolic function.

          2. Diagnosis of any of the following chronic diseases: hypertension, diabetes mellitus,
             renal insufficiency, congestive heart failure, hepatic insufficiency, biliary
             obstructive disorders, autoimmune disease, HIV, coronary artery disease, mental
             illness, and severe anemia.

          3. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other
             clinically relevant cardiac arrhythmias as determined by the investigator.

          4. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of the aortic or mitral valve.

          5. Unstable angina or myocardial infarction or cardiac surgery within the past 3 months.

          6. PCI (percutaneous coronary intervention) within the past 3 months.

          7. Stroke within the past 6 months.

          8. Bilateral renal artery stenosis or obstructive disorders, renal artery stenosis in a
             solitary kidney, post-renal transplant patients or patients with only one kidney.

          9. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

               -  SGPT (ALT) or SGOT (AST) &gt; 2.5 times the upper limit of normal range, or

               -  Serum creatinine &gt; 2.3 mg/dL (or &gt; 203 mol/L)

         10. Pre-menopausal women (last menstruation &lt;=1 year prior to signing informed consent)
             who:

               -  Have a positive urine pregnancy test (UPT) prior to randomisation (Visit 2 or
                  Visit 2.1 for subject participating in the clamp procedure)

               -  Are not surgically sterile, or

               -  Are nursing, or pregnant, or

               -  Are of child-bearing potential and are NOT practicing acceptable methods of birth
                  control, or do NOT plan to continue practicing an acceptable method throughout
                  the study and do not agree to periodic pregnancy testing during participation in
                  the study. Acceptable methods of birth control are limited to: Intra-Uterine
                  Device (IUD), oral, implantable or injectable contraceptives and estrogen patch.
                  No exceptions will be made.

         11. Hematocrit &lt; 35%.

         12. Primary aldosteronism.

         13. Hereditary fructose intolerance.

         14. History of drug or alcohol dependency within the previous 6 months.

         15. Currently participating in a weight loss program.

         16. Any investigational drug therapy within one month of randomisation or during the
             study.

         17. Known hypersensitivity to any component of the study drug (telmisartan or placebo).

         18. Any circumstances the Investigator feels participation in the study would hinder
             subject safety or completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA School of Medicine- Divison of Endocrinology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CA at SanDiego- Department of Endocrinology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harker Heights</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, Diabetes Research Group</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Riverside Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus Sygehus</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale Università di Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

